Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab-800CW fluorescence imaging for PitNET detection during transsphenoidal surgery
NL-OMON49831Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Oct 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of bevacizumab-IRDye800CW in pituitary neuroendocrine tumor (PitNET) (3 arms), sponsored by University Medical Center Groningen. Primary endpoints: Fluorescence discrimination of tumor versus non-tumor tissue and Safety. Started Oct 2020; status: active, not recruiting.
02
Drugs
bevacizumab-IRDye800CW
03
Conditions
pituitary neuroendocrine tumor (PitNET)
Beyond the preview
Go deeper on NL-OMON49831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49831.